View ValuationBioHarvest Sciences 将来の成長Future 基準チェック /56BioHarvest Sciencesは、61.1%と29%でそれぞれ年率61.1%で利益と収益が成長すると予測される一方、EPSはgrowで62.7%年率。主要情報61.1%収益成長率62.66%EPS成長率Personal Products 収益成長8.5%収益成長率29.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • May 16First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2025)First quarter 2026 results: US$0.12 loss per share. Revenue: US$8.51m (up 8.2% from 1Q 2025). Net loss: US$2.64m (loss widened 13% from 1Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.お知らせ • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Reported Earnings • Apr 02Full year 2025 earnings released: US$0.60 loss per share (vs US$0.80 loss in FY 2024)Full year 2025 results: US$0.60 loss per share (improved from US$0.80 loss in FY 2024). Revenue: US$34.5m (up 37% from FY 2024). Net loss: US$11.1m (loss narrowed 14% from FY 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in Europe.お知らせ • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026お知らせ • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.New Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$4.2m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding).お知らせ • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7お知らせ • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025お知らせ • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.お知らせ • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.042 loss in 2Q 2024)Second quarter 2025 results: US$0.23 loss per share (further deteriorated from US$0.042 loss in 2Q 2024). Revenue: US$8.52m (up 41% from 2Q 2024). Net loss: US$4.08m (loss widened 494% from 2Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.お知らせ • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025お知らせ • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.Reported Earnings • May 16First quarter 2025 earnings released: US$0.14 loss per share (vs US$0.48 loss in 1Q 2024)First quarter 2025 results: US$0.14 loss per share (improved from US$0.48 loss in 1Q 2024). Revenue: US$7.86m (up 47% from 1Q 2024). Net loss: US$2.34m (loss narrowed 65% from 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Europe.お知らせ • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025お知らせ • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025業績と収益の成長予測MUN:8MV0 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288710719312/31/202759-4-52412/31/202643-9-14-543/31/202635-11-9-7N/A12/31/202535-11-10-7N/A9/30/202533-12-9-7N/A6/30/202530-12-9-7N/A3/31/202528-9-10-7N/A12/31/202425-13-10-7N/A9/30/202422-17-10-7N/A6/30/202419-16-9-7N/A3/31/202416-18-10-8N/A12/31/202313-13-10-9N/A9/30/202311-8-9-8N/A6/30/20239-10-11-10N/A3/31/20237-10-10-8N/A12/31/20225-11-10-9N/A9/30/20224-10-10-9N/A6/30/20223-9-10-8N/A3/31/20222-5-10-8N/A12/31/20212-10-8-7N/A9/30/20212-11-7-6N/A6/30/20211-10-7-6N/A3/31/20211-13-5-4N/A12/31/20200-7-4-4N/A9/30/20200-5-3-3N/A6/30/20200-5-2-2N/A3/31/20200-4-3-3N/A12/31/20190-5N/A-2N/A9/30/20190-5N/A-3N/A12/31/20180-7N/A-3N/A12/31/20170-2N/A-2N/A12/31/20160-3N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 8MV0は今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: 8MV0今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 8MV0今後 3 年以内に収益を上げることが予想されます。収益対市場: 8MV0の収益 ( 29% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 8MV0の収益 ( 29% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 8MV0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 15:22終値2026/05/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioHarvest Sciences Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Matthew HewittCraig-Hallum Capital Group LLCAmit DayalH.C. Wainwright & Co.Anthony VendettiMaxim Group1 その他のアナリストを表示
Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Reported Earnings • May 16First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2025)First quarter 2026 results: US$0.12 loss per share. Revenue: US$8.51m (up 8.2% from 1Q 2025). Net loss: US$2.64m (loss widened 13% from 1Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.
お知らせ • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026
Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Reported Earnings • Apr 02Full year 2025 earnings released: US$0.60 loss per share (vs US$0.80 loss in FY 2024)Full year 2025 results: US$0.60 loss per share (improved from US$0.80 loss in FY 2024). Revenue: US$34.5m (up 37% from FY 2024). Net loss: US$11.1m (loss narrowed 14% from FY 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in Europe.
お知らせ • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026
お知らせ • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.
Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.
New Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$4.2m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding).
お知らせ • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7
お知らせ • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
お知らせ • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.
お知らせ • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.
Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.042 loss in 2Q 2024)Second quarter 2025 results: US$0.23 loss per share (further deteriorated from US$0.042 loss in 2Q 2024). Revenue: US$8.52m (up 41% from 2Q 2024). Net loss: US$4.08m (loss widened 494% from 2Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.
Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
お知らせ • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025
お知らせ • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.
Reported Earnings • May 16First quarter 2025 earnings released: US$0.14 loss per share (vs US$0.48 loss in 1Q 2024)First quarter 2025 results: US$0.14 loss per share (improved from US$0.48 loss in 1Q 2024). Revenue: US$7.86m (up 47% from 1Q 2024). Net loss: US$2.34m (loss narrowed 65% from 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Europe.
お知らせ • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
お知らせ • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025